184.89 USD
-5.6 (-2.94%)
184.89 USD
0 (0%)
Overall NUTX gets a fundamental rating of 7 out of 10. We evaluated NUTX against 100 industry peers in the Health Care Providers & Services industry. NUTX has an excellent financial health rating, but there are some minor concerns on its profitability. NUTX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make NUTX suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
NUTX had positive earnings in the past year.
In the past year NUTX had a positive cash flow from operations.
In the past 5 years NUTX reported 4 times negative net income.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of NUTX (11.83%) is better than 96.00% of its industry peers.
NUTX has a better Return On Equity (35.96%) than 95.00% of its industry peers.
With an excellent Return On Invested Capital value of 38.79%, NUTX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROIC | 38.79% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 11.63%, NUTX belongs to the best of the industry, outperforming 96.00% of the companies in the same industry.
NUTX's Operating Margin of 35.72% is amongst the best of the industry. NUTX outperforms 99.00% of its industry peers.
NUTX has a better Gross Margin (55.01%) than 78.00% of its industry peers.
In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NUTX is creating value.
The number of shares outstanding for NUTX has been increased compared to 1 year ago.
Compared to 5 years ago, NUTX has more shares outstanding
NUTX has a better debt/assets ratio than last year.
2.2 Solvency
NUTX has an Altman-Z score of 3.54. This indicates that NUTX is financially healthy and has little risk of bankruptcy at the moment.
NUTX's Altman-Z score of 3.54 is fine compared to the rest of the industry. NUTX outperforms 73.00% of its industry peers.
NUTX has a debt to FCF ratio of 1.87. This is a very positive value and a sign of high solvency as it would only need 1.87 years to pay back of all of its debts.
The Debt to FCF ratio of NUTX (1.87) is better than 85.00% of its industry peers.
A Debt/Equity ratio of 0.95 indicates that NUTX is somewhat dependend on debt financing.
The Debt to Equity ratio of NUTX (0.95) is worse than 60.00% of its industry peers.
Even though the debt/equity ratio score it not favorable for NUTX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 3.54 |
ROIC/WACC4.78
WACC8.11%
2.3 Liquidity
A Current Ratio of 3.20 indicates that NUTX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 3.20, NUTX belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
A Quick Ratio of 3.18 indicates that NUTX has no problem at all paying its short term obligations.
NUTX's Quick ratio of 3.18 is amongst the best of the industry. NUTX outperforms 87.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 873.64% over the past year.
NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 236.03%.
The Revenue has been growing by 222.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
3.2 Future
The Earnings Per Share is expected to grow by 44.72% on average over the next years. This is a very strong growth
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.11% yearly.
EPS Next Y76.08%
EPS Next 2Y19.66%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue Next Year216.85%
Revenue Next 2Y81.61%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.00, the valuation of NUTX can be described as very reasonable.
Based on the Price/Earnings ratio, NUTX is valued cheaper than 90.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.54. NUTX is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 14.79 indicates a correct valuation of NUTX.
Based on the Price/Forward Earnings ratio, NUTX is valued a bit cheaper than 76.00% of the companies in the same industry.
NUTX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10 | ||
| Fwd PE | 14.79 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 96.00% of the companies listed in the same industry.
89.00% of the companies in the same industry are more expensive than NUTX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.5 | ||
| EV/EBITDA | 4.05 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NUTX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NUTX's earnings are expected to grow with 44.72% in the coming years.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y19.66%
EPS Next 3Y44.72%
5. Dividend
5.1 Amount
NUTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
184.89
-5.6 (-2.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners34.93%
Inst Owner Change38.58%
Ins Owners2.39%
Ins Owner Change0%
Market Cap1.31B
Revenue(TTM)981.20M
Net Income(TTM)114.07M
Analysts82.22
Price Target255 (37.92%)
Short Float %15.87%
Short Ratio5.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend1.28
Dividend Growth(5Y)N/A
DP39.41%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)298.6%
Min EPS beat(2)-0.77%
Max EPS beat(2)597.97%
EPS beat(4)3
Avg EPS beat(4)2386.61%
Min EPS beat(4)-0.77%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.29%
Min Revenue beat(2)7.78%
Max Revenue beat(2)22.8%
Revenue beat(4)4
Avg Revenue beat(4)79.58%
Min Revenue beat(4)7.78%
Max Revenue beat(4)211.33%
Revenue beat(8)7
Avg Revenue beat(8)41.36%
Revenue beat(12)8
Avg Revenue beat(12)27.1%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.45%
PT rev (3m)3.45%
EPS NQ rev (1m)43.7%
EPS NQ rev (3m)43.7%
EPS NY rev (1m)347.18%
EPS NY rev (3m)93.95%
Revenue NQ rev (1m)33.94%
Revenue NQ rev (3m)42.31%
Revenue NY rev (1m)10.5%
Revenue NY rev (3m)29.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10 | ||
| Fwd PE | 14.79 | ||
| P/S | 1.33 | ||
| P/FCF | 7.5 | ||
| P/OCF | 7.35 | ||
| P/B | 4.12 | ||
| P/tB | 4.64 | ||
| EV/EBITDA | 4.05 |
EPS(TTM)18.49
EY10%
EPS(NY)12.5
Fwd EY6.76%
FCF(TTM)24.65
FCFY13.33%
OCF(TTM)25.15
OCFY13.6%
SpS138.78
BVpS44.86
TBVpS39.84
PEG (NY)0.13
PEG (5Y)N/A
Graham Number136.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROCE | 44.98% | ||
| ROIC | 38.79% | ||
| ROICexc | 49.2% | ||
| ROICexgc | 52.2% | ||
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% | ||
| FCFM | 17.76% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 17% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 117.81 | ||
| Cash Conversion | 47.91% | ||
| Profit Quality | 152.79% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 | ||
| Altman-Z | 3.54 |
F-Score8
WACC8.11%
ROIC/WACC4.78
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
EPS Next Y76.08%
EPS Next 2Y19.66%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
Revenue Next Year216.85%
Revenue Next 2Y81.61%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
EBIT growth 1Y1170.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1313.93%
EBIT Next 3Y163.37%
EBIT Next 5YN/A
FCF growth 1Y3319.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2258.26%
OCF growth 3YN/A
OCF growth 5YN/A
NUTEX HEALTH INC / NUTX FAQ
What is the ChartMill fundamental rating of NUTEX HEALTH INC (NUTX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to NUTX.
What is the valuation status for NUTX stock?
ChartMill assigns a valuation rating of 8 / 10 to NUTEX HEALTH INC (NUTX). This can be considered as Undervalued.
What is the profitability of NUTX stock?
NUTEX HEALTH INC (NUTX) has a profitability rating of 6 / 10.
What is the expected EPS growth for NUTEX HEALTH INC (NUTX) stock?
The Earnings per Share (EPS) of NUTEX HEALTH INC (NUTX) is expected to grow by 76.08% in the next year.
Can you provide the dividend sustainability for NUTX stock?
The dividend rating of NUTEX HEALTH INC (NUTX) is 0 / 10 and the dividend payout ratio is 39.41%.